Sales & Marketing News | pharmaphorum

News

CSL Vifor offers campaign to mollify EC in antitrust probe

CSL Vifor has said it is prepared to carry out a “comprehensive and multi-channel communication campaign” to address allegations by the EU that it disparaged one of its co

News

Astellas’ generic Myrbetriq defence knocked back again

Low-cost competition in the US to Astellas’ Myrbetriq for urinary incontinence has arrived after a court recommended denying an injunction on the launch of generics.

News

FDA clears Roche’s Alecensa for adjuvant use in NSCLC

Roche has broken new ground with its ALK inhibitor Alecenesa, becoming the first drug in the class to be approved by the FDA for adjuvant use after surgery in early-stage,

News

Brexit is ‘driving NHS medicines shortages,’ says report

A report from the Nuffield Trust has concluded that the UK is facing “constantly elevated medicine shortages,” including some antibiotics and epilepsy drugs, which are bei

News

GSK trails after Pfizer in 5-in-1 meningococcal vaccine race

The FDA has started a review of GSK’s five-in-one meningococcal vaccine, cueing up a decision in mid-February next year, as it tries to chase down a rival candidate from P

News

Boehringer says R&D pipeline is the best in its long history

Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that

CSL Vifor offers campaign to mollify EC in antitrust probe

Astellas’ generic Myrbetriq defence knocked back again

FDA clears Roche’s Alecensa for adjuvant use in NSCLC

Brexit is ‘driving NHS medicines shortages,’ says report

GSK trails after Pfizer in 5-in-1 meningococcal vaccine race

Boehringer says R&D pipeline is the best in its long history

Gilead strikes again, penning $5bn deal to buy Tubulis

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks